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Objective: Current guidelines recommend transarterial chemoembolization (TACE) as the standard
treatment for patients with intermediate stage hepatocellular carcinoma (HCC). However, choosing the
optimal treatments for patients with intermediate stage HCC still remains challenging for clinicians. The
purpose of our study was to compare the long-term survival of intermediate stage HCC patients treated
with surgical resection or TACE.
Methods: We obtained the baseline characteristics of 210 intermediate stage HCC patients that were
recruited for this study. Survival analysis was performed by KaplaneMeier method and a compar-
ison was made by log-rank test. Factors associated with survival rate were analyzed by Cox's
regression.
Results: There were 164 men and 46 women in the study group, with a mean age of 63 ± 11 years (range,
31e92 years). Among them, 67 patients (31.9%) received surgical resection and 143 patients (68.1%)
received TACE. Patients receiving surgical resection had a signiﬁcantly larger mean of maximum tumor
size (6.8 ± 2.8 vs. 5.8 ± 3.2 cm, P ¼ 0.016), higher ratio of solitary tumor (68.7% vs. 17.5%, P < 0.001), and
Child-Pugh class A (97% vs. 85%, P ¼ 0.009) than those with TACE. Patients receiving surgical resection
had a signiﬁcantly higher 1, 3, and 5 year survival rate compared with those treated with TACE (87.4%,
62.8% and 57.3% vs. 58.1%, 29.9% and 16.6%, P < 0.001). Multivariate analysis revealed that AFP level
>400 ng/ml [hazard ratio (HR):2.141, 95% CI: 1.091e4.203, P ¼ 0.027], Child B cirrhosis (HR: 4.726, 95%
CI: 1.021e21.884, P ¼ 0.047), and TACE (HR:3.391, 95% CI: 1.625e7.076, P ¼ 0.001) were independent risk
factors associated with poor prognosis.
Conclusions: Our results indicated that surgical resection provided superior survival beneﬁt than TACE to
patients with intermediate-stage HCC. This is in part attributable to advances in liver surgery which
make the resection of intermediate-stage HCC possible. Surgical resection should be considered ﬁrst for
patients with preserved liver function.
Copyright © 2016, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatocellular carcinoma (HCC) is one of the most common
cancers in the world. More than 75% of HCC cases occur in the Farrology, Ren-Ai Branch, Taipei
9, Taiwan.
ang).
ncology Society.
Society. Production and hosting byEast and Southeast Asia.1 Only a small proportion of patients have
their HCC detected in an early curable stage, thus the worldwide 5-
year survival rate of HCC only slightly increased from 5 to 15% over
the past two decades.2 Themajor causes of unsatisfactory prognosis
of HCC include degree of liver function impairment and heteroge-
neous nature of HCC, which affect treatment outcome.3 Cumulative
evidence also suggests that accurate assessment and staging of
HCC, and correct designation of optimal treatments may prolong
survival rate of HCC.4,5 Among current HCC staging systems, the
Barcelona Clinic Liver Cancer (BCLC) classiﬁcation is the one of mostElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Ren-Ai multidisciplinary model for treatment of intermediate stage HCC.
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be categorized as BCLC intermediate-stage, patients are asymp-
tomatic (performance status score, 0) with multinodular tumors
but without vascular invasion or extrahepatic spread. The median
survival time was 16 months for patients with BCLC intermediate-
stage HCC.6 Based on the AASLD guideline, a revised version of the
Barcelona Clinic Liver Cancer (BCLC) staging system by the Amer-
ican Association for the Study of Liver Diseases (AASLD),4,5 trans-
arterial chemoembolization (TACE) has been recognized as an
effective option for those with intermediate stage HCC.4,5,8
Although TACE has been considered a palliative treatment for
unresectable HCC, previousmeta-analyses indicated that treatment
with TACE is associated with a signiﬁcantly higher 2-year survival
rate than those patients receiving conservative management or
suboptimal therapies.9,10 Nonetheless, the improvement in long-
term survival is not clear. In addition, TACE-associated adverse
events include post-embolization syndrome, relevant liver function
deterioration, ascites and gastrointestinal bleeding; such adverse
events are not unusual.11 Because intermediate stage HCC includes
both Child-Turcotte-Pugh (CTP) class A and B patients, ascertaining
the optimal treatments for these patients still remains a substantial
challenge. Recent advances in liver surgery make the resection of
intermediate stage HCC possible.12e15 It is therefore important to
clarify the optimal and effective therapy for intermediate stage HCC
patients. The purpose of our study was to compare the long-term
survival of intermediate stage HCC patients treated with surgical
resection or TACE.
2. Materials and methods
2.1. Patients
A total of 210 newly diagnosed intermediate stage HCC patients,
including 67 patients (31.9%) with surgical resection and 143 pa-
tients (68.1%) with TACE, were retrospectively enrolled from Ren-Ai
Branch, Taipei City Hospital between January 1998 and May 2013.
The liver function reserve was assessed by the Child-Turcotte-Pugh
(CTP) score.16 The diagnosis of HCC was histologically conﬁrmed in
all patients receiving surgical resection and 87 (60.8%) of patients
with TACE treatment. The remaining 56 (39.2%) patients with TACE
treatment were conﬁrmed by typical imaging exhibited through
arterial enhancement and portal venous washout on multiphasic
computed tomography (CT) or magnetic resonance imaging
(MRI).4,5 According to the BCLC staging system, the intermediate
stage HCC was deﬁned as CTP class A and B cirrhotic patients with
large or multifocal HCC who do not have cancer-related symptoms
and do not have macrovascular invasion or extrahepatic spread.8
Treatment for intermediate HCC was guided by a multidisci-
plinary model (Fig. 1). In the weekly multidisciplinary conference,
all patients were discussed, and their eligibility for surgical resec-
tion or TACE was evaluated based on images, laboratory analyses
and medical history. This study protocol was approved by the
institutional review board of Taipei City Hospital.
2.2. Biochemical and serological testing
The biochemical tests were measured using routine automated
methods. The HBsAg and anti-HCV were assayed using commercial
kits (General Biological HBsAg RIA, General Biological Cooperation,
Taiwan. HCV EIA II. Abbott Laboratories, North Chicago, IL, USA).
2.3. Procedure of surgical resection
Indications for surgery were: 1) CTP classiﬁcation grade of A or
B, 2) performance status test was grade 0 or 1, 3) solitary ormultiple tumors which were clinically resectable, or 4) the pres-
ence of appropriate residual liver volume.17 Intraoperative ultra-
sound was routinely performed to determine tumor location and
precise deﬁnition of tumorevessel relationship. Anatomic
segmental resections were performed for potentially curative
operation. Additionally, the resection margin was more than 1 cm.
2.4. Procedure of TACE
The standardized procedure of TACE was described previously.18
In brief, TACE procedures were performed in a dedicated angiog-
raphy suite DFP8000D (Toshiba Medical Systems, Otawara, Japan)
with 4Fr J-Curve catheters (Terumo Medical Corporation, Tokyo,
Japan) inserted via the right external femoral artery puncture,
guided by a matching mandrel (Terumo Medical Corporation,
Tokyo). The J-Curve catheter tip was placed in the celiac axis oriﬁce,
and one set of digital subtraction angiography was performed. For
patients with S5 or S6 tumors which might draw their tumor
vessels from superior mesenteric branches, a set of digitally-
subtracted superior mesenteric angiography was also performed.
If the tumor stains and the supplying vessels were not well-
demonstrated by the above angiograms, further superselective
angiograms were performed including angiograms of the common
hepatic artery, proper hepatic artery, right or left hepatic arteries,
and sometimes even the smaller segmental branches. Embolization
was performed from the appropriate site, which usually was the
proper hepatic artery for multiple bilateral tumors, and the right or
left hepatic arteries for unilateral tumors. The embolization agents
were ethiodized oil Lipiodol® (Guerbet, Villepinte, France) and
absorbable gelatin sponge Surgifoam® (Ethicon, Somerville, NJ,
USA), and the chemotherapy agents were mitomycin and doxoru-
bicin. The dosage of lipiodol and gelatin sponge was based on a
Table 1
Demographic and clinical characteristics of 210 patients with intermediate
stage hepatocellular carcinoma treated with surgical resection and trans-
arterial chemoembolization.
Characteristics TACE
(n ¼ 143)
Surgical resection
(n ¼ 67)
P value
Age 64 ± 11 62 ± 11 0.156
60 years (%) 53 (37.1) 31 (46.3) 0.228
>60 years (%) 90 (62.9) 36 (53.7)
Male, n (%) 108 (76) 56 (84) 0.214
Positive for HBsAg, n (%) 75 (52) 40 (60) 0.338
Positive for anti-HCV, n (%) 56 (39) 16 (24) 0.056
Alcoholism, n (%) 27 (19) 12 (18) 1.0
CTP class, n (%) 0.009
A 121 (85) 65 (97)
B 22 (15) 2 (3)
Mean maximum tumor size 5.8 ± 3.2 6.8 ± 2.8 0.016
Tumor size > 3 cm, n (%) 119 (83.2%) 64 (96) 0.014
Tumor size > 5 cm, n (%) 75 (52.4%) 56 (83.6%) <0.001
Tumor number (1/2/S3) 25/33/85 46/14/7 <0.001
Biochemistriesa, mean ± SD
Albumin (g/dL) 3.44 ± 0.38 3.86 ± 0.48 0.003
Bilirubin (mg/dL) 1.25 ± 0.89 0.92 ± 0.51 0.003
AST (U/L) 93 ± 104 60 ± 53 0.015
ALT (U/L) 83 ± 100 61 ± 49 0.095
PT (second) 12.2 ± 1.63 11.9 ± 1.45 0.337
AFP <400 (ng/ml), n, % 92 (64) 44 (66) 1.0
Diabetes mellitus, n (%) 46 (32) 16 (24) 0.257
Survival rate <0.001
1 year 58.1% 87.4%
3 years 29.9% 62.8%
5 years 16.6% 57.3%
AFP: alpha-fetoprotein; ALT: alanine aminotransferase; AST: aspartate
aminotransferase; CTP: Child-Turcotte-Pugh; HBV: hepatitis B virus; HCV:
hepatitis C virus; PT: prothrombin time.
a Missing data in one patient with TACE treatment.
Fig. 2. The cumulative survival curve of 210 patients with intermediate stage hepa-
tocellular carcinoma treated with surgical resection and transarterial chemo-
embolization (TACE).
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copy, with a typical dose ranging from 3 to 15 mL of Lipiodol®. The
dosage of mitomycin and doxorubicin were determined by patient
weight, and a typical dose of mitomycinwas 4e8mg and 20e30mg
for doxorubicin.
2.5. Patient follow-up
After surgical resection or TACE, all patients underwent regular
follow-up, including a liver function test, measurement of serum
alpha fetoprotein (AFP) levels and abdominal ultrasonography at
an interval of 2e3 months. For patients with TACE treatment, the
presence of viable tumor was conﬁrmed on multiphasic CT or MRI
one to two months after TACE. Thereafter, TACE was repeated in
2e3 month intervals until complete tumor necrosis. When
intrahepatic recurrence was suspected, further investigation was
carried out using CT or MRI. Patients with recurrence would
receive the appropriate treatment options based on clinical de-
cision making.
2.6. Statistical analysis
Data were analyzed by chi-square test, Fisher's exact test, Stu-
dent's t-test and logistic regression where appropriate. Overall
survival was measured from the day of HCC diagnosis and when
patient survival was conﬁrmed through June 2013. Cumulative
survival was calculated according to the KaplaneMeier method.
The association of potential risk factors of mortality was deter-
mined by univariate and multivariate logistic regression. All tests
were two-tailed and a P value of less than 0.05 was considered
statistically signiﬁcant.
3. Results
Baseline clinical characteristics of the 210 intermediate stage
HCC patients are shown in Table 1. There were 164 men (78.1%)
and 46 women (21.9%), with a mean age of 63 ± 11 years (range:
31e92 years). Among them, 67 patients (31.9%) received surgical
resection and 143 patients (68.1%) received TACE. There were no
signiﬁcant differences in terms of sex, age, prevalence of HBV/HCV
infection and ratio of AFP >400 ng/ml between patients treated
with surgical resection and TACE. Compared to patients receiving
TACE treatment, patients with surgical resection had a signiﬁ-
cantly larger mean of maximum tumor size (6.8 ± 2.8 vs.
5.8 ± 3.2 cm, P ¼ 0.016), a higher ratio of tumor number <3 (89.6%
vs. 40.6%, P < 0.001), CTP class A cirrhosis (97% vs. 85%, P ¼ 0.009),
higher serum albumin level (3.86 ± 0.48 vs. 3.44 ± 0.38 g/dL,
P ¼ 0.003), lower serum total bilirubin level (0.92 ± 0.51 vs.
1.25 ± 0.89 mg/dL, P ¼ 0.003), and lower serum AST level (60 ± 53
vs. 93 ± 104 U/L, P ¼ 0.015).
During a median (25e75 percentile) follow-up period of 17
(39e7) months, patients receiving surgical resection had a signiﬁ-
cantly higher 1, 3, and 5 year survival rate compared with those
treated with TACE (87.4%, 62.8% and 57.3% vs. 58.1%, 29.9% and
16.6%, P < 0.001) (Fig. 2). The median survival time was 70 months
in patients receiving surgical resection and 17months in those with
TACE (P < 0.001).
Cox regression analysis for risk factors associated with survival
was shown in Table 2. Serum levels of total bilirubin [hazard ratio
(HR):1.838, 95% CI:1.147e2.944, P ¼ 0.011], AST (HR: 1.007, 95%
CI:1.001e1.014, P ¼ 0.025), prothrombin time (HR: 1.318, 95%
CI:1.032e1.684, P ¼ 0.027), AFP level > 400 ng/ml (HR:2.220, 95%
CI: 1.192e4.135, P ¼ 0.012), multiple tumor (HR:2.245, 95% CI:
1.245e4.049, P ¼ 0.007), CTP class B cirrhosis (HR:7.268, 95%
CI:1.659e31.832, P ¼ 0.008) and TACE treatment (HR:3.99, 95%CI:2.162e7.366, P < 0.001) were signiﬁcantly associated with
mortality in univariate analysis. Since albumin, total bilirubin and
prothrombin time are the components of Child classiﬁcation, only
Child classiﬁcation was included in multivariate logistic analysis.
Multivariate analysis revealed that AFP level >400 ng/ml (HR:2.141,
95% CI: 1.091e4.203, P ¼ 0.027), CTP class B cirrhosis (HR: 4.726,
95% CI: 1.021e21.884, P ¼ 0.047) and TACE (HR:3.391, 95% CI:
1.625e7.076, P ¼ 0.001) were independent risk factors associated
with poor prognosis.
Table 2
Univariate and multivariate Cox regression analysis of factors associated with survival in 210 patients with intermediate stage hepatocellular carcinoma treated with surgical
resection and transarterial chemoembolization.
Factor Univariate Multivariate
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
Gender 0.359
female 1
male 0.72 (0.356e1.454)
Age 0.86
60 years 1
>60 years 1.053 (0.593e1.869)
Creatinine 2.088 (0.486e8.974) 0.322
Albumin 1.003 (0.998e1.007) 0.219
Bilirubin 1.838 (1.147e2.944) 0.011
AST 1.007 (1.001e1.014) 0.025 1.003 (0.997e1.009) 0.3
ALT 1.003 (0.998e1.007) 0.219
Prothrombin time 1.318 (1.032e1.684) 0.027
AFP 0.012 0.027
400 1 1
>400 2.220 (1.192e4.135) 2.141 (1.091e4.203)
Etiology 0.387
HBV 1
HCV 1.35 (0.684e2.664)
Alcoholism 0.487
No 1
Yes 0.777 (0.382e1.582)
Diabetes mellitus 0.420
No 1
Yes 0.778 (0.423e1.423)
Tumor size 0.922
3 cm 1
>3 cm 1.043 (0.451e2.409)
Tumor size 0.637
5 cm 1
>5 cm 0.869 (0.484e1.559)
Tumor number 0.007 0.935
Single 1 1
Multiple 2.245 (1.245e4.049) 1.031 (0.498e2.132)
Child classiﬁcation 0.008 0.047
A 1 1
B 7.268 (1.659e31.832) 4.726 (1.021e21.884)
Treatment <0.0011 0.001
Resection 1 1
TACE 3.99 (2.162e7.366) 3.391 (1.625e7.076)
AFP: alpha-fetoprotein; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CTP: Child-Turcotte-Pugh; HBV: hepatitis B virus; HCV: hepatitis C virus; TACE:
transarterial chemoembolization.
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termediate stage hepatocellular carcinoma patients with CTP class
A and a tumor number less than three. Similar to the entire cohort,
patients receiving surgical resection had a signiﬁcantly higher 1, 3,
and 5 year survival rate compared with those treated with TACE
(89.2%, 65.2% and 58.7% vs. 63%, 41.4% and 18.4%, P < 0.001) (Fig. 3).
The median survival time was 70 months in patients receiving
surgical resection and 32 months in those with TACE (P < 0.001).Fig. 3. The cumulative survival curve of 108 intermediate stage hepatocellular carci-
noma patients with Child-Turcotte-Pugh class A and tumor number less than 3 treated
with surgical resection and transarterial chemoembolization (TACE).4. Discussion
Our results indicated that surgical resection provided superior
survival beneﬁt than TACE to patients with intermediate stage HCC,
irrespective of CTP class A or B cirrhosis. Surgical resection was
identiﬁed as an independent factor associated with survival by Cox
regression analysis.
According to the BCLC staging system and recommended
treatment strategy (AASLD guideline), TACE has been recognized as
an effective treatment option for those with intermediate stage
HCC.4,5 Cumulative meta-analysis of published randomized
controlled trials further indicates that patient survival is signiﬁ-
cantly improved after TACE.10 However, the 1-year mortality of
intermediate stage HCC patients receiving TACE still remains
C.-L. Lin et al. / Journal of Cancer Research and Practice 3 (2016) 34e3838unsatisfactory.18 It would appear that TACE may not be the optimal
therapy for all intermediate stage HCC patients.
Curative treatments, which include surgical resection, percuta-
neous ablation and liver transplantation, were considered as the
optimal treatment for patients with very early/early stage HCC by
BCLC criteria.4,5 Furthermore, advances in liver surgery make the
resection of large and/or multifocal HCC possible.19e22 Therefore,
surgical resection may be a safe and effective therapy for a certain
segment of intermediate stage HCC patients. A previous study of
intermediate stage HCC, CTP class A cirrhotic patients reported that
patients receiving surgical resection had better survival than those
with TACE.23,24 In our study, most patients (97%) who received
surgical resection had CTP class A cirrhosis. Similar to previous
studies, our results showed that patients with surgical resection
had signiﬁcantly higher long-term survival rates than patients with
TACE. In addition, CTP class B cirrhosis was identiﬁed as indepen-
dent risk factors associated with poor prognosis. Taken together,
the selection of ideal candidates with preserved liver function for
surgical resection should improve long-term survival of interme-
diate stage HCC.
In our study, AFP level >400 ng/ml was a risk factor associated
with poor prognosis. Serum AFP level has been recognized as a poor
prognostic factor through poor tumor biological behavior, such as
tumor multiplicity, poor differentiation and carcinoma cell embolus,
as well asmoderate/severe cirrhosis.18,25e27 Therefore, incorporation
of AFP level to current HCC staging systems is recommended in
evaluating prognosis and subclassiﬁcation for intermediate stage
HCC patients to tailor optimal therapeutic modality.28
There are several limitations of this study. First, as a retrospec-
tive study design, the existence of patient selection bias for surgical
resection or TACE should be considered. Second, the standard se-
lection criteria for surgical resection are not well established. In
addition, the frequency of TACE administration for individual pa-
tients varies in our study, which was inﬂuenced by tumor pro-
gression and severity of cirrhosis during the follow-up period.
Therefore, large cohort studies are required to further evaluate the
optimum treatment strategy for intermediate stage HCC patients.
In conclusion, our results indicated that surgical resection pro-
vides superior survival beneﬁt than TACE to patients with inter-
mediate stage HCC. Advances in liver surgery make the resection of
intermediate stage HCC possible. Surgical resection should be
considered ﬁrst for patients with preserved liver functions. How-
ever, standard selection criteria for surgical resection are needed. It
is foreseen that surgical resection will play an important role in
treatment for intermediate stage HCC, now and into the future.
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